Abstract 3417
Background
Immune-checkpoint inhibitors (ICI) have recently been used in many types of cancers including non-small cell lung cancer (NSCLC). Interstitial lung disease associated with ICI (ICI-ILD) is a serious immune-related adverse event. However, comprehensive clinical characterization of ICI-ILD is still lacking.
Methods
We retrospectively analyzed clinical and imaging data of all consecutive ICI treated patients in Kurashiki Central Hospital (Okayama, Japan) between January 2016 and March 2019. We elucidated clinical characteristics, radiopathological patterns, therapeutic strategies and outcomes of ICI-ILD and analyzed the prognostic factor of ICI-ILD.
Results
Among 316 (222 NSCLC and 94 non-NSCLC) treated with ICI, 35 (11.1%) were diagnosed as ICI-ILD. Of those, NSCLC/gastric cancer/urinary cancer/head and neck cancer/malignant lymphoma were 26/2/2/4/1, respectively: mean age was 69.3 ± 9.0 years; 29 (82.9%) were men; 19 (54.3%) received Nivolumab monotherapy and 10 (28.6%) received Pembrolizumab monotherapy; Best objective response rate until ICI-ILD diagnosis was 48.6% (11/35); The median time (range) from ICI introduction to ICI-ILD was 57 (22-155) days. CTCAE grade 1/2/3 + 4/5 was 10 (28.6%)/14 (40.0%)/7 (20.0%)/4 (11.4%), respectively; Organizing pneumonia was found in 57.1% (20/35) in CT and 66.7% (4/6) in transbronchial lung biopsy; Lymphocyte differential count of bronchoalveolar lavage fluid (range) was 41 (33-60) %; 26 (74.3%) were treated with corticosteroid; 29 (82.9%) had ICI-ILD improved but 6 (17.1%) did not. The median survival time was significantly different between ILD improved group and non-improved group (17.1 months vs 0.8 months, p < 0.001). Multivariate Cox regression analysis demonstrated that only ICI-ILD improvement is a significant prognostic factor (HR: 0.03; 95% CI, 0.003-0.305; p = 0.003).
Conclusions
In our real-world experience, half of ICI-ILD patients had a response toward malignancy. Organizing pneumonia was the most common radiopathological pattern and lymphocyte differential count of bronchoalveolar lavage fluid was elevated in ICI-ILD. If ICI-ILD does not improve, its prognosis may be very poor.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3073 - 1 patient 3 different advance Ca nurse’s roles: symptom management&continuum care through a joint approach in a clinical case
Presenter: Catarina Almeida
Session: Poster Display session 3
Resources:
Abstract
4527 - Identification of malnutrition risk factors in patients with cancer in the first nursing visit
Presenter: Amaia Valverde
Session: Poster Display session 3
Resources:
Abstract
2904 - Engaging Cancer Survivors, Healthcare Providers and Advocates in The Development of a Colorectal Cancer Survivorship Information Resource: A Participatory Action Research Study
Presenter: Amanda Drury
Session: Poster Display session 3
Resources:
Abstract
3435 - Medical nurses’ experiences of the care-needs of adult patients with a primary brain tumour
Presenter: Jamila Mohammed
Session: Poster Display session 3
Resources:
Abstract
857 - Feasibility and acceptability of a mHealth intervention to increase colonoscopy uptake among Chinese first-degree relatives: a pilot cluster randomized controlled trial
Presenter: Yang Bai
Session: Poster Display session 3
Resources:
Abstract
1087 - Cancer patient participation and compliance in microbiome sample collection: an oncology research nurse’s experience
Presenter: Julie Malo
Session: Poster Display session 3
Resources:
Abstract
2783 - Implementing Digital Individual Care plans for Patients with Head and Neck cancer- Challenges and opportunities
Presenter: Helena Ullgren
Session: Poster Display session 3
Resources:
Abstract
1152 - The Effect of the Short-term and Long-term Compassion Fatigue Resiliency Program on the Quality of Life, Perceived Stress and Psychological Resilience of Oncology-Hematology Nurses
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
1172 - Competing risk analyses of overall survival and cancer-specific survival in patients with orbital rhabdomyosarcoma after surgery: a large cohort study
Presenter: Yu Zhang
Session: Poster Display session 3
Resources:
Abstract
5949 - Communication of genetic information to family members in hereditary cancers and healthcare providers’ role
Presenter: Carla Pedrazzani
Session: Poster Display session 3
Resources:
Abstract